Top Performing Drug – Enbrel (June Edition)
PharmaShots
JUNE 28, 2023
Consistent with prior periods, Enbrel continued to lose market share, and this decline was compounded by a reduction in the growth rate of the rheumatology market as a result of COVID-19. Some of its approved biosimilars are mentioned below along with the regulatory bodies they are approved by*. This list is not an exhaustive list.
40 
Let's personalize your content